increas
complex
conduct
multiregion
trial
evolv
regulatori
environ
contribut
unpreced
new
challeng
use
patientreport
outcom
measur
prom
within
clinic
trial
paper
present
challeng
potenti
solut
method
realworld
exampl
situat
review
industri
patientreport
outcom
pro
expert
posit
conclus
increas
pursuit
new
therapeut
target
chang
regulatori
environ
busi
pressur
expand
clinic
trial
countri
significantli
increas
complex
confirmatori
clinic
studi
incorpor
prom
decis
particip
collabor
effort
endpoint
develop
proceed
independ
made
context
compet
prioriti
drug
develop
timelin
drug
differenti
strategi
need
patientrel
valu
messag
depth
sponsor
pipelin
within
specif
diseas
area
studi
logist
critic
import
factor
concept
cultur
relev
respond
literaci
level
qualiti
crosscultur
adapt
prom
must
evalu
integr
confirmatori
clinic
trial
awar
issu
relat
pro
multiregion
studi
enabl
compani
better
plan
studi
interpret
result
wellcontrol
clinic
trial
effect
mean
identifi
safe
efficaci
pharmaceut
treatment
confirmatori
clinic
trial
phase
trial
intend
provid
firm
evid
efficaci
safeti
claim
clinic
trial
primari
endpoint
mainli
combin
physiolog
clinic
respons
measur
howev
addit
endpoint
patient
report
outcom
pro
often
includ
patient
direct
report
central
overal
evalu
drug
effect
fulli
understand
patient
feel
function
respons
treatment
understand
critic
assess
safeti
efficaci
may
provid
import
insight
gener
patientrelev
inform
pharmaceut
product
pro
collect
increas
number
clinic
trial
via
standard
questionnair
design
measur
explicit
concept
construct
symptom
activ
limit
health
statu
hrqol
qol
questionnair
also
call
instrument
scale
diari
checklist
measur
collect
refer
prom
new
product
approv
almost
quarter
treatmentbenefit
claim
grant
us
fda
base
prom
absenc
object
marker
diseas
instanc
symptom
irrit
bowel
syndrom
migrain
pain
treatment
efficaci
must
report
directli
patient
instanc
pro
primari
endpoint
confirmatori
clinic
trial
recent
review
prorel
label
grant
fda
show
pro
primari
endpoint
product
least
one
pro
claim
pro
may
also
key
secondari
endpoint
either
independ
close
associ
primari
endpoint
regul
often
requir
verif
sponsor
primari
endpoint
use
coprimari
secondari
endpoint
exampl
alzheim
diseas
suffici
achiev
improv
adascog
without
show
improv
daili
activ
perform
copd
show
improv
lung
function
fev
insuffici
without
evid
improv
physic
activ
patientreport
symptom
addit
regul
may
request
assess
differ
aspect
patient
experi
use
pro
assess
multipl
impact
sle
suggest
fda
ema
regulatori
bodi
recogn
implic
debilit
diseas
suggest
addit
standard
clinic
assess
diseas
activ
bilag
sledai
use
patientreport
outcom
instrument
measur
relev
import
sle
symptom
patientperceiv
abil
function
perform
daili
activ
assess
qualiti
life
via
lupu
qol
mani
challeng
associ
inclus
prom
clinic
trial
challeng
follow
identif
concept
measur
understand
trial
may
conduct
tradit
market
may
give
rise
unexpect
variat
stem
cultur
influenc
impact
pro
time
access
crosscultur
adapt
prom
reliabl
captur
patient
view
abil
collect
data
appropri
time
point
interpret
data
recent
mani
chang
environ
within
pharmaceut
industri
oper
wherea
chang
enabl
compani
better
integr
prom
mrct
chang
introduc
new
challeng
impact
integr
prom
clinic
trial
paper
aim
discuss
challeng
provid
potenti
strategi
address
three
main
recent
develop
affect
use
prom
pharmaceut
industri
chang
regulatori
environ
increas
number
new
emerg
previous
undiagnos
diseas
impact
public
health
chang
natur
mrct
us
fda
formal
set
evid
standard
prom
use
clinic
trial
support
product
label
patientreport
outcom
healthrel
qualiti
life
qualiti
life
pro
measur
unit
state
food
drug
administr
alzheim
diseas
assess
scalecognit
subscal
chronic
obstruct
pulmonari
diseas
forc
expiratori
volum
system
lupu
erythematosu
european
medicin
associ
british
isl
lupu
assess
group
system
lupu
erythematosu
diseas
activ
index
mrct
claim
prom
must
meet
requir
describ
fda
guidanc
industri
patientreport
outcom
measur
use
medic
product
develop
support
label
claim
label
claim
must
support
appropri
design
investig
use
prom
demonstr
measur
concept
underli
claim
contrast
ema
produc
reflect
paper
provid
broad
recommend
use
prom
clinic
trial
addit
ema
develop
biomark
qualif
program
qualif
program
provid
formal
mechan
ratifi
clinic
trial
endpoint
includ
new
exist
prom
fda
also
issu
draft
guidanc
guidanc
industri
qualif
process
drug
develop
tool
draft
guidanc
describ
new
qualif
process
drug
develop
tool
includ
among
thing
biomark
pro
date
neither
program
qualifi
new
prom
use
clinic
trial
improv
effici
effort
develop
valid
prom
meet
regulatori
requir
collabor
initi
us
europ
collabor
industri
regulatori
bodi
academia
distinct
departur
tradit
approach
singl
sponsor
develop
measur
singl
specif
drug
develop
program
within
confin
competit
environ
move
prom
develop
precompetit
environ
stakehold
recogn
valu
pool
resourc
expertis
enabl
success
develop
prom
collabor
also
includ
close
involv
regul
focu
improv
test
method
process
evalu
safeti
effect
medic
product
fda
pharmaceut
industri
togeth
launch
cpi
cpi
fda
nation
strategi
transform
way
fdaregul
medic
product
develop
evalu
manufactur
cpi
collabor
fda
independ
initi
call
pro
consortium
form
aim
implement
cpi
effort
creat
collabor
among
major
regulatori
agenc
worldwid
medic
product
industri
academ
institut
patient
advocaci
organ
primari
aim
pro
consortium
develop
qualifi
public
avail
pro
instrument
facilit
fda
review
medic
product
standard
pro
endpoint
initi
five
pro
consortium
work
group
topic
chosen
list
diseasescondit
fda
receiv
multipl
request
advic
best
measur
pro
endpoint
clinic
trial
eight
work
group
current
seek
prom
qualif
fda
initi
similar
cpi
call
imi
also
launch
europ
earli
european
feder
pharmaceut
industri
associ
european
commiss
wherea
goal
cpi
imi
initi
improv
effici
drug
develop
impetu
cpi
initi
stem
regulatori
concern
impetu
imi
came
need
make
drug
discoveri
develop
process
europ
effici
enhanc
europ
competit
pharmaceut
sector
present
organ
europ
similar
us
pro
consortium
develop
pro
within
imi
manag
part
initi
specif
one
follow
five
diseas
area
brain
disord
cancer
metabol
infecti
inflammatori
diseas
one
prom
current
develop
within
imi
initi
focu
understand
patient
experi
copd
initi
similar
sens
encourag
biopharmaceut
industri
collabor
precompetit
environ
combat
ineffici
increas
cost
declin
product
escal
complex
regulatori
requir
govern
initi
share
public
privat
partnership
implic
collabor
effort
drug
manufactur
discuss
later
paper
biopharmaceut
industri
face
challeng
address
grow
list
new
emerg
diseas
target
current
drug
develop
mani
diseas
defin
either
new
previous
unrecogn
diseas
appear
first
time
diseas
known
increas
incid
signific
public
health
implic
exampl
includ
agerel
diseas
sarcopenia
infecti
diseas
sar
avian
influenza
chronic
diseas
obes
underresearch
diseas
inclus
bodi
myositi
addit
increas
number
medicin
product
develop
treat
rare
diseas
orphan
drug
expans
drug
develop
new
diseas
area
new
regulatori
market
access
environ
led
need
mani
new
diseasespecif
prom
howev
collabor
initi
mention
previous
unlik
abl
meet
demand
industri
imi
initi
specif
certain
diseas
area
activ
pro
consortium
much
base
capac
manag
staff
addit
work
group
base
level
interest
member
firm
regulatori
need
driven
larg
need
cut
cost
improv
recruit
effici
increas
number
clinic
trial
especi
confirmatori
clinic
trial
move
us
western
europ
emerg
market
eastern
europ
latin
america
asia
exampl
averag
annual
growth
rate
base
data
avail
number
clinic
trial
carri
china
poland
increas
critic
path
initi
innov
medicin
initi
sever
acut
respiratori
syndrom
respect
wherea
declin
us
uk
formul
success
pro
strategi
goe
beyond
identifi
appropri
construct
measur
select
suitabl
instrument
also
requir
consider
key
qualiti
standard
welldesign
prom
assess
patient
across
broad
spectrum
diseas
sever
convers
poorli
design
prom
may
incap
identifi
treatment
chang
measur
construct
mild
sever
patient
pro
highli
relev
patient
group
studi
maxim
qualiti
data
collect
discuss
relat
choic
prom
provid
elsewher
literatur
basi
recent
develop
discuss
previous
challeng
face
research
prom
includ
confirmatori
clinic
trial
summar
follow
four
categori
impact
cultur
literaci
pro
data
complex
studi
logist
prom
includ
mrct
intens
intern
resourc
alloc
regulatori
dilemma
wherea
confirmatori
studi
involv
popul
studi
center
around
world
phase
studi
preced
confirmatori
studi
often
base
rel
smaller
number
patient
limit
number
center
europ
north
america
region
henc
phase
studi
variat
pro
data
attribut
influenc
cultur
region
may
pronounc
howev
samples
calcul
confirmatori
studi
base
variat
found
phase
data
often
neglect
includ
possibl
ad
variat
due
patient
cultur
languag
variat
pro
data
mrct
influenc
mani
factor
includ
avail
qualiti
crosscultur
valid
pro
measur
cultur
repres
among
studi
popul
literaci
level
target
patient
popul
ideal
approach
cultur
adapt
creat
prom
input
particip
countri
intend
clinic
trial
howev
rare
done
given
stringent
timelin
drug
develop
program
mani
pro
questionnair
first
develop
singl
languag
often
us
english
translat
languag
meet
need
clinic
trial
translat
prom
also
call
crosscultur
adapt
lengthi
process
ensur
linguist
cultur
psychometr
equival
among
variou
languag
version
although
recognit
need
cultur
valid
translat
new
applic
methodolog
rigor
employ
translat
prom
recent
despit
recent
develop
cultur
equival
prom
use
clinic
trial
alway
guarante
two
main
reason
firstli
prom
develop
prior
releas
pro
guidanc
fda
may
employ
appropri
methodolog
rigor
requir
recent
report
translat
assess
prom
cultur
contribut
greatest
discrep
origin
target
version
secondli
cultur
equival
may
chang
time
languag
cultur
neither
static
discret
entiti
constantli
evolv
chang
consid
accept
one
point
time
may
futur
time
point
exampl
portugues
version
mani
prom
chang
follow
spell
reform
introduc
import
point
note
emot
may
adequ
translat
differ
mean
interpret
across
cultur
exampl
feel
frustrat
shame
annoy
anger
may
express
differ
differ
cultur
lead
unexpect
variat
report
symptom
well
sever
symptom
exampl
mental
health
impact
irrit
bowel
syndrom
measur
shown
differ
patient
greec
sweden
report
symptom
associ
menopaus
vari
among
cultur
asian
cultur
depress
often
express
somat
upset
stomach
loss
appetit
rather
emot
feel
blue
addit
vari
attitud
among
cultur
toward
diseas
obes
aid
may
also
impact
pro
data
mrct
exampl
fear
stigma
discrimin
associ
hiv
part
africa
prevent
patient
report
symptom
seek
treatment
respond
literaci
level
thu
abil
read
comprehend
instruct
question
respons
option
abil
util
data
captur
technolog
also
may
impact
qualiti
pro
data
mrct
research
plan
studi
includ
develop
countri
note
literaci
rate
countri
vari
significantli
urban
rural
area
male
femal
exampl
indian
censu
report
literaci
rate
urban
area
rural
area
literaci
rate
also
vari
significantli
male
femal
african
middl
eastern
countri
influenc
geograph
region
cultur
uniqu
pro
data
variat
health
care
outcom
due
factor
socioeconom
statu
cultur
belief
frequent
report
howev
maintain
integr
trial
achiev
desir
accuraci
reliabl
overal
assess
effect
safeti
studi
drug
import
consid
influenc
languag
cultur
pro
especi
pro
primari
endpoint
knowledg
cultur
nuanc
within
individu
countri
well
literaci
level
intend
target
patient
popul
essenti
success
outcom
confirmatori
clinic
trial
pro
increas
generaliz
prom
knowledg
best
gather
local
nativespeak
health
profession
may
provid
unbias
judgment
propos
tool
basi
knowledg
studi
appropri
design
prom
improv
either
appropri
select
modif
instruct
variabl
control
impact
variat
qualiti
studi
data
minim
addit
integr
new
technolog
use
ivr
may
increas
abil
nonliter
patient
particip
collect
pro
data
final
issu
rare
discuss
pro
literatur
relat
assumpt
patient
respond
question
relat
feel
accord
without
influenc
anyon
els
evid
challeng
assumpt
often
found
literatur
relat
ethic
challeng
obtain
inform
consent
biomed
research
mani
groupori
cultur
often
opinion
famili
commun
leader
dictat
individu
particip
clinic
trial
similarli
cultur
power
patientbas
factor
socioeconom
background
cast
gender
agein
relat
next
kin
health
care
provid
determin
particip
clinic
trial
patient
decis
take
part
clinic
trial
sole
decis
much
credibl
place
opinion
feel
relat
treatment
outcom
includ
exist
prom
mrct
comprehens
background
inform
must
gather
essenti
select
appropri
version
pro
measur
use
obtain
necessari
translat
receiv
permiss
requir
author
andor
copyright
holder
pay
licens
fee
verifi
avail
certif
translat
satisfi
need
institut
review
board
us
independ
ethic
committe
europ
furthermor
import
ensur
adequ
suppli
necessari
translat
instrument
appropri
datacollect
format
eg
paper
case
report
form
digit
devic
avail
patient
appropri
care
must
also
taken
determin
validationequival
data
avail
support
mode
prom
administr
mix
mode
administr
mani
instrument
distinct
version
use
differ
situat
vari
recal
period
subpopul
exampl
aqlq
origin
version
publish
standard
version
avail
selfor
intervieweradminist
version
version
specif
children
similarli
version
publish
version
publish
version
avail
recal
period
standard
form
recal
period
acut
form
studi
team
underestim
effort
involv
obtain
necessari
translat
requir
multiregion
studi
mani
countri
requir
one
languag
exampl
patient
recruit
clinic
trial
india
pro
measur
may
suppli
offici
recogn
languag
india
even
small
countri
like
switzerland
requir
pro
measur
three
languag
german
french
italian
local
dialect
addit
linguist
similar
languag
spoken
differ
countri
may
differ
significantli
exampl
separ
translat
french
may
requir
franc
belgium
canada
separ
translat
tamil
may
requir
use
india
sri
lanka
malaysia
singapor
use
offici
languag
countri
particip
mrct
guid
select
languag
pro
measur
may
also
mislead
exampl
although
latvian
offici
languag
latvia
third
popul
latvia
speak
russian
moreov
swedish
ethic
committe
often
insist
patient
access
danish
version
pro
measur
studi
center
sweden
situat
near
danish
border
case
integr
danish
version
relev
prom
plan
even
studi
center
denmark
particip
studi
effort
involv
ensur
avail
appropri
languag
version
use
confirmatori
clinic
trial
immens
studi
team
must
awar
locat
studi
center
composit
expect
patient
popul
center
effort
target
requir
languag
version
train
administ
prom
critic
collect
high
qualiti
data
site
staff
must
prepar
provid
clear
instruct
particip
complet
studi
questionnair
ensur
success
execut
studi
administr
also
fulli
train
respond
queri
concern
patient
andor
caregiv
appropri
eg
patient
concern
confidenti
respons
pro
measur
even
data
suggest
treatment
benefit
ambigu
instruct
patient
complet
prom
may
result
regulatori
concern
review
singl
item
assess
itch
ustekinumab
stelara
janssen
biotech
inc
horsham
pennsylvania
inclus
pro
mrct
time
consum
resourc
intens
sponsor
pharmaceut
compani
requir
among
activ
translat
questionnair
organ
datacaptur
method
prepar
train
materi
studi
coordin
patient
compil
brief
book
seek
scientif
advic
inclus
prom
studi
protocol
also
requir
contribut
mani
function
intern
sponsor
compani
clinic
data
manag
biostatist
epidemiolog
regulatori
commun
outcom
research
absenc
exist
prom
fit
requir
purpos
develop
novel
prom
costli
take
long
year
collabor
effort
may
even
take
longer
gap
analysi
earli
drug
develop
essenti
assess
need
new
instrument
initi
activ
ensur
time
integr
instrument
confirmatori
clinic
trial
consider
intern
resourc
requir
integr
prom
success
mrct
often
intern
resourc
secur
intend
pro
object
specifi
must
strateg
document
target
market
profil
target
product
profil
agreement
among
function
manag
pro
object
essenti
satisfi
product
regulatori
need
commerci
need
wherea
agreement
would
clearli
delin
pro
primari
endpoint
may
pro
nonprimari
endpoint
unless
intern
process
place
seek
time
agreement
lack
commit
parti
often
translat
poor
implement
prom
clinic
trial
lead
suboptim
data
miss
opportun
compani
face
three
option
pro
expect
play
major
role
regulatori
decis
make
first
need
accommod
differ
requir
prefer
differ
health
author
demonstr
treatment
benefit
second
relat
path
develop
prom
requir
specif
studi
compani
choos
particip
collabor
effort
weight
valid
evid
like
great
regulatori
feedback
known
follow
tradit
path
shorter
singl
sponsor
develop
novel
prom
specif
drug
develop
program
third
option
reli
exist
measur
fda
ema
appear
differ
accept
prom
support
label
claim
fda
demonstr
reluct
provid
label
claim
pro
concept
symptom
wherea
ema
current
appear
take
flexibl
approach
approv
label
claim
higher
order
concept
hrqol
ema
action
indic
greater
open
inclus
scale
provid
appropri
develop
adequ
psychometr
properti
use
justifi
studi
popul
although
much
emphasi
prom
fit
purpos
sinc
releas
fda
pro
guidanc
recent
review
pro
label
fda
cover
period
show
pro
label
claim
grant
basi
measur
tradit
accept
review
divis
fda
ema
diseasespecif
guidelin
frequent
request
pro
endpoint
even
occasion
suggest
specif
questionnair
pro
primari
coprimari
endpoint
moreov
although
fda
typic
recommend
hrqol
primari
endpoint
ema
recommend
hrqol
primari
endpoint
clinic
trial
cystic
fibrosi
coprimari
endpoint
copd
hematolog
malign
differ
requir
prefer
lead
increas
number
prom
must
includ
specif
clinic
trial
exampl
addit
demonstr
improv
pain
level
ra
import
includ
haqdi
show
function
improv
fda
guidanc
industri
furthermor
ra
studi
inclus
healthrel
qualiti
life
measur
suggest
ema
addit
prom
may
includ
gener
addit
relev
inform
base
improv
fatigu
work
product
health
statusa
total
five
prom
addit
measur
joint
pain
although
differ
requir
differ
regulatori
agenc
uniqu
pro
data
inclus
multipl
prom
satisfi
fda
ema
well
payer
may
significantli
increas
complex
associ
studi
logist
well
burden
patient
complet
multipl
questionnair
cover
similar
domain
multipl
factor
influenc
decis
whether
pharmaceut
compani
choos
invest
anoth
qualif
process
develop
pro
proceed
independ
develop
valid
process
instead
reli
upon
exist
measur
may
may
appropri
label
claim
importantli
decis
must
made
earli
product
developmentoften
start
phase
studi
target
product
profil
earli
stage
develop
inform
may
limit
allow
determin
pro
concept
studi
exampl
target
popul
may
specif
enough
impact
treatment
target
popul
may
certain
end
phase
studi
therefor
compani
must
decid
collabor
qualif
process
choos
standalon
develop
new
prom
tool
util
defin
support
primari
endpoint
diseas
area
compani
invest
long
term
altern
determin
collabor
go
alon
may
determin
drug
develop
timelin
given
collabor
natur
need
consensu
build
within
work
group
regulatori
bodi
qualif
pro
instrument
may
requir
year
homegrown
measur
depend
upon
diseas
area
may
typic
much
shorter
develop
time
howev
trade
weight
evid
agreement
amass
collabor
effort
compar
possibl
achiev
singl
entiti
third
option
particip
consortia
standalon
develop
reli
exist
tool
sinc
label
claim
fda
still
base
establish
familiar
prom
flexibl
approach
shown
ema
compani
press
develop
time
resourc
may
still
reli
tradit
use
prom
gener
valu
messag
especi
wellresearch
diseas
depress
regulatori
path
wellestablish
howev
approach
may
suitabl
quest
provid
patient
relev
inform
especi
fda
pro
guidanc
continu
integr
drug
develop
process
baldwin
colleagu
note
regulatori
hurdl
gener
pro
base
label
claim
hinder
effort
bring
new
medicin
market
time
manner
compani
may
invest
innov
method
util
social
media
commun
patientbas
valu
messag
gain
competit
advantag
address
need
key
stakehold
rheumatoid
arthriti
health
assess
questionnairedis
index
outsid
regulatori
arena
payer
provid
patient
increas
number
new
therapeut
target
affect
global
public
health
chang
regulatori
environ
busi
pressur
result
increas
number
countri
particip
clinic
trial
signific
impact
confirmatori
clinic
studi
incorpor
prom
assess
recent
chang
within
regulatori
environ
us
europ
challeng
pharmaceut
compani
develop
pro
strategi
satisfi
health
author
global
regulatori
guidanc
document
fda
guidanc
pro
fda
ema
qualif
process
sought
simplifi
process
increas
transpar
accept
use
import
prom
collabor
effort
regulatori
bodi
pharmaceut
industri
pro
expert
advanc
field
pro
research
regulatori
accept
prom
howev
despit
progress
sponsor
must
tailor
regulatori
strategi
specif
need
drug
develop
program
import
weight
fit
purpos
evid
provid
qualif
process
must
compar
compet
prioriti
drug
develop
timelin
drug
differenti
strategi
need
patientrel
valu
messag
depth
sponsor
pipelin
within
specif
diseas
area
consider
often
involv
need
multipl
stakehold
compet
prioriti
leav
studi
team
unabl
formul
effect
pro
strategi
regulatori
accept
wider
number
prom
larger
number
diseas
area
may
facilit
develop
futur
pro
strategi
differ
regulatori
need
fda
ema
may
alway
exist
team
need
pois
meet
sometim
differ
criteria
technolog
advanc
data
collect
enabl
control
may
help
eas
logist
complic
execut
mrct
regard
data
collect
challeng
howev
factor
cultur
relev
concept
literaci
rate
respond
control
must
depend
upon
qualiti
crosscultur
adapt
prom
must
continu
part
evalu
process
integr
pro
confirmatori
clinic
trial
corollari
issu
cross
cultur
adapt
must
awar
pro
data
may
influenc
patient
may
reflect
patient
experi
alon
instead
reflect
complex
interact
patient
famili
commun
physicianpati
relationship
team
must
awar
need
special
challeng
requir
prepar
resourc
need
collect
qualiti
evalu
pro
data
patient
voic
may
continu
emerg
context
confirmatori
clinic
trial
awar
issu
relat
pro
multiregion
studi
enabl
compani
better
plan
studi
integr
pro
interpret
result
